SCHEMBL8395502

SCHEMBL8395502

O=C(Nc1cccc2c(S(=O)(=O)O)cccc12)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
CASP3 P42574 1/20 0.52
PLAU P00749 1/20 0.52
TYMS P04818 2/20 0.50
PTPN1 P18031 1/20 0.49
MGLL Q99685 1/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
POLB P06746 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
MAOB P27338 1/20 0.44
TRPV1 Q8NER1 4/20 0.44
CASP1 P29466 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29892518 1.00 NPC1 (0.56) NPC1RAB9ACASP3PLAUTYMS
SCHEMBL29892522 1.00 NPC1 (0.56) NPC1RAB9ACASP3PLAUTYMS
SCHEMBL8042550 0.89 NPC1 (0.54) NPC1RAB9ACASP3PLAUTYMS
SCHEMBL8060495 0.88 NPC1 (0.53) NPC1RAB9ACASP3PLAUTYMS
SCHEMBL9125523 0.77 NPC1 (0.58) NPC1RAB9ACASP3PLAUMGLL
SCHEMBL27786325 0.76 NPC1 (0.57) NPC1RAB9ACASP3PLAUPTPN1
SCHEMBL10902168 0.76 TTR (0.53) RAB9ACA12CA1CA2CA9
SCHEMBL1339026 0.75 NPC1 (0.62) NPC1RAB9APOLBHPGD
SCHEMBL9093600 0.75 PLAU (0.55) NPC1RAB9ACASP3PLAUPTPN1
SCHEMBL3786444 0.75 NPC1 (0.68) NPC1RAB9ACASP3PLAUPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228447-A1 SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS GEN1E LIFESCIENCES INC. 2024-07-11 US disclosed
EP-4313959-A1 SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS GEN1E Lifesciences Inc. (US) 2024-02-07 EP disclosed
CN-117120422-A Substituted naphthyl P38 alpha mitogen-activated protein kinase inhibitors GEN1E生命科学公司 2023-11-24 CN disclosed
US-20230227417-A1 SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS GEN1E LIFESCIENCES INC. 2023-07-20 US disclosed
US-20230227417-A1 SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS GEN1E LIFESCIENCES INC. 2023-07-20 US disclosed
WO-2022204046-A1 SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS GEN1E LIFESCIENCES INC. (US) 2022-09-29 WO disclosed
EP-0752986-B1 N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LTD (GB) 1999-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227417-A1 SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS MAPK1, MAPK8, MAPKAPK2 NPC1 486/4885RAB9A 1915/4885CASP3 2197/4885
US-20240228447-A1 SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS MAPK1, MAPK8, MAPKAPK2 NPC1 486/4885RAB9A 1915/4885CASP3 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.